BMRN – BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc.

BMRN

$56.56

Name : BioMarin Pharmaceutical Inc.

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $10,954,405,888.00

EPSttm : -0.1

BioMarin Pharmaceutical Inc.

$56.56

3.04%

$1.78

BMRN — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

7.39

Margin Of Safety %

Put/Call OI Ratio

0.32

EPS Next Q Diff

1.45

EPS Last/This Y

-0.12

EPS This/Next Y

3.34

Price

58.32

Target Price

90.81

Analyst Recom

1.55

Performance Q

-14.88

Upside

-106.0%

Beta

0.23

Ticker: BMRN

22 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-10-13	BMRN	54.39	0.29	0.26	36882
2026-10-14	BMRN	55.18	0.29	0.01	36837
2026-10-15	BMRN	56.06	0.30	0.73	35898
2026-10-16	BMRN	54.69	0.30	0.78	36996
2026-10-19	BMRN	54.67	0.32	0.14	31230
2026-10-20	BMRN	56.48	0.32	0.04	31540
2026-10-21	BMRN	55.24	0.30	0.05	32562
2026-10-22	BMRN	56.66	0.30	0.23	32748
2026-10-23	BMRN	55.96	0.30	0.21	32970
2026-10-26	BMRN	55.76	0.30	0.26	33260
2026-10-27	BMRN	55.38	0.30	0.23	33656
2026-10-28	BMRN	56.01	0.30	0.05	33539
2026-10-29	BMRN	57.46	0.30	0.09	33629
2026-10-30	BMRN	58.55	0.30	0.14	34894
2026-11-02	BMRN	57.47	0.30	0.36	35351
2026-11-03	BMRN	55.63	0.30	0.39	37172
2026-11-04	BMRN	57.15	0.31	0.26	43819
2026-11-05	BMRN	56.11	0.31	0.01	43836
2026-11-06	BMRN	56.01	0.31	0.63	43918
2026-11-09	BMRN	57.18	0.31	0.43	43928
2026-11-10	BMRN	57.12	0.31	1.15	44133
2026-11-11	BMRN	58.33	0.32	0.21	44184
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

22 items 1 of 1

22 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-10-13	BMRN	54.37	767.1	545.1	4.70
2026-10-14	BMRN	55.17	767.1	564.8	4.70
2026-10-15	BMRN	56.06	767.1	574.6	4.70
2026-10-16	BMRN	54.71	695.4	541.8	4.63
2026-10-19	BMRN	54.66	695.4	556.0	4.63
2026-10-20	BMRN	54.66	695.4	556.0	4.63
2026-10-21	BMRN	56.48	557.1	576.2	4.46
2026-10-22	BMRN	56.66	472.4	572.1	4.37
2026-10-23	BMRN	55.99	472.4	549.2	4.37
2026-10-26	BMRN	55.74	-100.0	554.0	3.63
2026-10-27	BMRN	55.35	-100.0	551.9	3.51
2026-10-28	BMRN	56.03	-100.0	563.3	3.51
2026-10-29	BMRN	57.42	-100.0	571.6	3.51
2026-10-30	BMRN	58.51	-100.0	567.0	3.51
2026-11-02	BMRN	57.47	-100.0	545.0	3.51
2026-11-03	BMRN	55.69	-100.0	579.3	3.51
2026-11-04	BMRN	57.13	-100.0	624.1	3.16
2026-11-05	BMRN	56.12	-100.0	598.0	3.16
2026-11-06	BMRN	56.00	-100.0	607.3	3.02
2026-11-09	BMRN	57.19	-100.0	621.3	3.02
2026-11-10	BMRN	57.12	-100.0	608.0	3.03
2026-11-11	BMRN	58.32	-100.0	621.2	3.03
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

22 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-10-13	BMRN	-0.83	1.37	6.03
2026-10-14	BMRN	-0.83	1.37	6.03
2026-10-15	BMRN	-0.83	1.37	6.03
2026-10-16	BMRN	-0.83	1.37	6.03
2026-10-19	BMRN	-0.83	1.38	6.03
2026-10-20	BMRN	-0.83	1.38	6.03
2026-10-21	BMRN	-0.83	1.38	6.03
2026-10-22	BMRN	-0.83	1.38	6.03
2026-10-23	BMRN	-0.83	1.38	6.03
2026-10-26	BMRN	-0.83	1.28	6.03
2026-10-27	BMRN	-0.83	1.28	6.31
2026-10-28	BMRN	-0.83	1.28	6.31
2026-10-29	BMRN	-0.83	1.28	6.31
2026-10-30	BMRN	-0.83	1.28	6.31
2026-11-02	BMRN	-0.83	1.16	6.31
2026-11-03	BMRN	-0.83	1.16	6.31
2026-11-05	BMRN	-0.83	1.16	6.31
2026-11-06	BMRN	-0.83	1.16	6.31
2026-11-09	BMRN	-0.83	-0.17	6.30
2026-11-10	BMRN	-0.83	-0.17	6.30
2026-11-11	BMRN	-0.83	-0.17	7.39
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

0.02

Avg. EPS Est. Current Quarter

-0.11

Avg. EPS Est. Next Quarter

1.47

Insider Transactions

-0.83

Institutional Transactions

-0.17

Beta

0.23

Average Sales Estimate Current Quarter

1025

Average Sales Estimate Next Quarter

1052

Fair Value

72.09

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

50.5

Max Drawdown 5-Year %

-57.6

Target Price

90.81

P/E

Forward P/E

9.07

PEG

0.15

P/S

3.06

P/B

1.81

P/Free Cash Flow

20.25

EPS

-0.1

Average EPS Est. Cur. Y

3.03

EPS Next Y. (Est.)

6.37

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-0.52

Relative Volume

0.74

Return on Equity vs Sector %

-26.7

Return on Equity vs Industry %

-7.1

EPS 1 7Days Diff

-0.5

EPS 1 30Days Diff

-1.33

EBIT Estimation

621.2

◆ BMRN Healthcare

$58.33

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

2/20

Pullback

11/25

Volume

9/15

Valuation

20/20

TP/AR

1/10

Options

7/10

RSI

54.6

Range 1M

79.6%

Sup Dist

3.1%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

1/25

Growth

23/30

Estimates

4/20

Inst/Vol

1/15

Options

10/10

EPS Yr

68.2%

EPS NY

112.5%

52W%

40.2%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟢 BUY +159.3% upside

Quality

8/30

Valuation

26/30

Growth

18/25

Stability

6/10

LT Trend

0/5

Upside

+159.3%

Quality

MoS

24%

BMRN — P/E HistoricalBiotechnology

BioMarin Pharmaceutical Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 3221

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; and KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease. The company's products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California.

BMRN

Latest News

—

Caricamento notizie per BMRN…

stock quote shares BMRN – BioMarin Pharmaceutical Inc. Stock Price stock today

news today BMRN – BioMarin Pharmaceutical Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch BMRN – BioMarin Pharmaceutical Inc. yahoo finance google finance

stock history BMRN – BioMarin Pharmaceutical Inc. invest stock market

stock prices BMRN premarket after hours

ticker BMRN fair value insiders trading

BMRN – BioMarin Pharmaceutical Inc.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: BMRN

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

Last Quarter Act. EPS

Average EPS Est. Cur. Y